Zobrazeno 1 - 10
of 1 131
pro vyhledávání: '"PCV13"'
Autor:
Claire von Mollendorf, Munkhchuluun Ulziibayar, Cattram D. Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, John de Campo, Margaret de Campo, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Eileen M. Dunne, Catherine Satzke, Tuya Mungun, E. Kim Mulholland
Publikováno v:
Emerging Infectious Diseases, Vol 30, Iss 3, Pp 490-498 (2024)
Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the
Externí odkaz:
https://doaj.org/article/4146740e6fa843209e433f625d4dee75
Autor:
Alexander V. Zhestkov, Maxim O. Zolotov, Elizaveta V. Kadantseva, Tatyana R. Nikitina, Andrey D. Protasov
Publikováno v:
Инфекция и иммунитет, Vol 13, Iss 6, Pp 1192-1196 (2023)
Until recently, HIV infection does not lose its relevance. In 2022, 630 000 people died and 1.3 million people became infected with the human immunodeficiency virus (HIV). HIV-positive persons develop more infectious diseases than healthy people do;
Externí odkaz:
https://doaj.org/article/07d061b71c524bed9792a7b4b1b347a2
Autor:
Yuanze Du, Yi Wang, Ting Zhang, Juanjuan Li, Hewei Song, Yuanyuan Wang, Yifei Xu, Jingwen Cui, Ming Yang, Zengwu Wang, Xiuyun Wu, Chunping Wang
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 193-206 (2023)
Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13. Areas covered We
Externí odkaz:
https://doaj.org/article/0fd3dfeebd8e4fd180feabc3654c6128
Autor:
Kazuhiro Ishikawa, Nobuyoshi Mori
Publikováno v:
IDCases, Vol 36, Iss , Pp e01936- (2024)
Given the high mortality rate of invasive pneumococcal disease (IPD) in hematopoietic stem cell transplant (HSCT) recipients, vaccination is recommended. These recipients respond to most vaccines; however, their immune response is typically weaker du
Externí odkaz:
https://doaj.org/article/cb41af9552cc4d789f4b0073b7310b96
Autor:
Xing Shi, Sandip Patil, Qing Wang, Zihao Liu, Chunqin Zhu, Heping Wang, Yunshen Chen, Liqiang Li, Liang Yang, Yuejie Zheng, Shaowei Dong, Yanmin Bao
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 13 (2024)
BackgroundPCV13 introduction in China has led to a significant reduction of vaccine serotype Streptococcus pneumoniae. However, non-vaccine serotypes with highly resistance and invasiveness were often reported in the post-pneumococcal conjugate vacci
Externí odkaz:
https://doaj.org/article/b856c041406149a5bd2a4e654b709ff3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michele Wilson, Cheryl McDade, Anna Trisia Beby-Heijtel, Angela Waterval-Overbeek, Vishalini Sundaram, Johnna Perdrizet
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 7, Pp 1809-1821 (2023)
Abstract Introduction The 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix) was introduced into the Dutch pediatric national immunization program (NIP) starting in 2011. However, there is substantial pneumococcal disease burden due to incre
Externí odkaz:
https://doaj.org/article/e4f2250be4154cf89e7baf3d8ac9eb14
Autor:
Hamaguchi M, Tsubata Y, Yoshihara K, Nakao M, Amano Y, Nakashima K, Hotta T, Okimoto T, Hamaguchi S, Sutani A, Isobe T
Publikováno v:
International Journal of General Medicine, Vol Volume 16, Pp 2125-2132 (2023)
Megumi Hamaguchi,1 Yukari Tsubata,1 Ken Yoshihara,1 Mika Nakao,1 Yoshihiro Amano,1 Kazuhisa Nakashima,1 Takamasa Hotta,2 Tamio Okimoto,1 Shunichi Hamaguchi,3 Akihisa Sutani,4 Takeshi Isobe1 1Division of Medical Oncology and Respiratory Medicine, Depa
Externí odkaz:
https://doaj.org/article/3d0e16147f564b8792c99f2e5a4545be
Autor:
Johnna Perdrizet, Emily K. Horn, Kyla Hayford, Lindsay Grant, Rachid Barry, Liping Huang, Cheryl McDade, Michele Wilson
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 5, Pp 1351-1364 (2023)
Abstract Introduction This study estimates the annual population-level impact of 13-valent pneumococcal conjugate vaccine (PCV13) infant national immunization programs (NIPs) on vaccine-type and non-vaccine type invasive pneumococcal disease (IPD) in
Externí odkaz:
https://doaj.org/article/a02a168a132041509e51588b17b29c26
Autor:
Tianyan Hu, Eric M. Sarpong, Yan Song, Nicolae Done, Qing Liu, Esteban Lemus-Wirtz, James Signorovitch, Salini Mohanty, Thomas Weiss
Publikováno v:
Pneumonia, Vol 15, Iss 1, Pp 1-15 (2023)
Abstract Background Pneumonia is the most serious form of acute respiratory infection and Streptococcus pneumoniae is a leading cause of pediatric bacterial pneumonia. Pneumococcal conjugate vaccines were introduced in the United States (US) in 2000
Externí odkaz:
https://doaj.org/article/23c8e558c53241389668108740fe0d6e